Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: foot + 1,640 + web  Related to the article below (Last Update: 8/5/2008)

I-80 Work Update
Gant Daily, PA -
The HARS (Highway Advisory Radio System) are in use and motorist can tune their radio to 1640 AM for the latest construction advisories. ...

Sportinglife.co.za
GLORIOUS GOODWOOD DAY ONE BLOG
Sportinglife.co.za, UK - Jul 29, 2008
0945: First market mover of the day - Players Please in the Deltica Summer Stakes at 1640. Mark Johnston's charge is 8s from 10s with BetDirect, ...
Source: Google News

Evaluating ADAPT: a hybrid instructional model combining Web-based and classroom components -
BW Tuckman - Computers & Education, 2002 - Elsevier
... Learning Laboratory, The Ohio State University, 1640 Neil Avenue ... in the course, and
in a relational, Web-based database ... one half of a 4600 square foot on-campus ...

Relationship between the surrogate anthropometric measures, foot length and chest circumference and … -
LC Mullany, GL Darmstadt, SK Khatry, SC LeClerq, … - European Journal of Clinical Nutrition, 2006 - nature.com
... Full text access provided to Googlebot Access by Web Services. ... Scatter plots of
(a) chest circumference and (b) foot length measures vs birth weight (n=1640). ...

The Bishops' Wars: Charles I's Campaigns against Scotland, 1638-1640
MB Young - JSTOR
... flawed protagonist drawn increasingly into a web of his ... unstable the situation was
by 1640, followed by ... For all their grumbling and foot-dragging, the nobility ...

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors -
MS Kramer, N Cutler, J Feighner, R Shrivastava, J … - Science, 1998 - sciencemag.org
... that does not support current Web standards. ... 1640 - 1645 DOI: 10.1126/science.281.5383.
1640. ... ventral tegmental area after inescapable foot shock, immobilization ...

[BOOK] Cheap Print and Popular Piety, 1550-1640
T Watt - 1991 - books.google.com
... CHEAPPRINTAND POPULAR PIETY, 1550-1640 Tessa Watt Page 2. Cambridge Studies in Early
Modern British History CHEAP PRINT AND POPULAR PIETY, 1550-1640 ...

[BOOK] Centuries and Styles of the American Chair, 1640-1970
RC Bishop - 1972 - Dutton

-
HJ White - US Patent 3,528,592, 1970 - Google Patents
... prepared at 1640 psig (115.3 kg./cm. ... The belt on which the web of overlapping plexifila-
ments is ... A15 foot (4.57 meters) long wire 0.016 inch (0.41 mm.) in ...

[BOOK] " Myne Owne Ground": Race and Freedom on Virginia's Eastern Shore, 1640-1676
TH Breen, S Innes - 2004 - books.google.com
... Breen, TH "Myne owne ground" : race and freedom on Virginia's Eastern Shore,
1640-1676 / TH ... of the series can be found on the "Africans in America" web site. ...
-

… Gardam and Michelle J. Jarvis, Kluwer Law International, The Hague, 2001, ISBN 90-411-1640-0, 290 pp …
PV Sellers - Leiden Journal of International Law, 2004 - Cambridge Univ Press
... is not reliant on access to the web, is handy ... International, The Hague, 2001, ISBN
90-411-1640-0, 290 pp ... Such foot-dragging, the authors contend, was dwarfed by ...

Immune response to Newcastle disease virus in chicken lines divergently selected for cutaneous … -
KA Ahmed, VK Saxena, A Ara, KB Singh, NR … - International Journal of Immunogenetics, 2007 - Blackwell Synergy
... values over that of initial 0-h values (mean of left and right foot-web thickness ...
aliquots per line containing 2 ? 10 6 cells mL 1 were made in RPMI-1640 medium ...

Source: Google Scholar

Pexiganan, Topical Anti-Infective For Treatment Of Diabetic Foot Infection
MacroChem Corporation (OTCBB: MACM - News) has announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.
Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the U.S. Diabetic foot ulcers in the approximately 20 million diabetics in the US alone are a major concern and burden to both patients and healthcare system. There is also a lack of effective topical anti-infectives to treat diabetic foot infection. Accordingly, we believe that pexiganan could fill an important unmet medical need for a topical anti-infective treatment and provide a significant commercial opportunity in an addressable market of approximately 3.5 million diabetic foot infections annually."

The option agreement gives MacroChem a 90-day exclusive right to enter into a license agreement with Genaera. MacroChem paid Genaera $250,000 on execution of the option agreement.

Both EcoNail and pexiganan would be developed to treat diseases of the foot predominantly treated by the same prescribing specialists, namely podiatrists. Both products would potentially be of interest to a larger number of physician specialists and primary care physicians as well. EcoNail is the company's patented lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA®. Patients participating in the EcoNail study will receive 48 weeks of treatment and will undergo efficacy assessments using standard criteria of nail appearance and mycology. However, the Company will collect and evaluate 24-week interim data later this year. This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase 3 as soon as possible.
About MacroChem

MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our proprietary enhancer, SEPA®: EcoNail, to treat fungal infection of the nail and Opterone®, to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin. For more information visit our website, http://www.macrochem.com/.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com/.

Source: Bill Douglass
MacroChem
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.